n -苄基-2-氟苯酰胺作为EGFR/HDAC3双靶点抑制剂治疗三阴性乳腺癌的发现及构效关系

IF 2.2 4区 医学 Q3 CHEMISTRY, MEDICINAL
Bioorganic & Medicinal Chemistry Letters Pub Date : 2025-12-01 Epub Date: 2025-08-05 DOI:10.1016/j.bmcl.2025.130362
Gong-Hui Ge, Shuai Guo, Ting-Ting Li, Yan-Ping Wang, Li-Rong Liu, Wen-Hui Yu, Hao Hu, Yi-Meng Zheng, Jing-Han Yan, Ying-Hao Sun, Jing-Wei Liang, Fan-Hao Meng, Ting-Jian Zhang
{"title":"n -苄基-2-氟苯酰胺作为EGFR/HDAC3双靶点抑制剂治疗三阴性乳腺癌的发现及构效关系","authors":"Gong-Hui Ge, Shuai Guo, Ting-Ting Li, Yan-Ping Wang, Li-Rong Liu, Wen-Hui Yu, Hao Hu, Yi-Meng Zheng, Jing-Han Yan, Ying-Hao Sun, Jing-Wei Liang, Fan-Hao Meng, Ting-Jian Zhang","doi":"10.1016/j.bmcl.2025.130362","DOIUrl":null,"url":null,"abstract":"<p><p>Epidermal growth factor receptor (EGFR) and histone deacetylase 3 (HDAC3) synergistically drive malignant progression in triple-negative breast cancer (TNBC). In this study, a series of N-benzyl-2-fluorobenzamide derivatives (11-43) were identified as EGFR/HDAC3 dual-target inhibitors. Among them, compound 38 exhibited the most promising activity, with IC₅₀ values of 20.34 nM and 1.09 μM against EGFR and HDAC3, respectively. Molecular modeling revealed that the 2-fluorobenzamide moiety of 38 chelates with Zn<sup>2+</sup> in the active channel of HDAC3, while the 4-fluorobenzyl group occupies the ATP-binding pocket of EGFR, exercising a dual-target binding function. In vitro experiments demonstrated that 38 exhibited superior anti-proliferative activity (IC₅₀ = 1.98 μM) against MDA-MB-231 cells compared to chidamide (IC₅₀ = 24.37 μM), inducing 74.15 % inhibition of cell migration and 57.4 % late-stage apoptosis. In vivo studies revealed that 38 (30 mg/kg/day) suppressed tumor growth by 34.78 % without significant toxicity. Collectively, 38 represents a novel dual EGFR/HDAC3 inhibitor that shows promising potential for providing new therapeutic insights into TNBC treatment.</p>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":" ","pages":"130362"},"PeriodicalIF":2.2000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Discovery and structural-activity relationship of N-benzyl-2-fluorobenzamides as EGFR/HDAC3 dual-target inhibitors for the treatment of triple-negative breast cancer.\",\"authors\":\"Gong-Hui Ge, Shuai Guo, Ting-Ting Li, Yan-Ping Wang, Li-Rong Liu, Wen-Hui Yu, Hao Hu, Yi-Meng Zheng, Jing-Han Yan, Ying-Hao Sun, Jing-Wei Liang, Fan-Hao Meng, Ting-Jian Zhang\",\"doi\":\"10.1016/j.bmcl.2025.130362\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Epidermal growth factor receptor (EGFR) and histone deacetylase 3 (HDAC3) synergistically drive malignant progression in triple-negative breast cancer (TNBC). In this study, a series of N-benzyl-2-fluorobenzamide derivatives (11-43) were identified as EGFR/HDAC3 dual-target inhibitors. Among them, compound 38 exhibited the most promising activity, with IC₅₀ values of 20.34 nM and 1.09 μM against EGFR and HDAC3, respectively. Molecular modeling revealed that the 2-fluorobenzamide moiety of 38 chelates with Zn<sup>2+</sup> in the active channel of HDAC3, while the 4-fluorobenzyl group occupies the ATP-binding pocket of EGFR, exercising a dual-target binding function. In vitro experiments demonstrated that 38 exhibited superior anti-proliferative activity (IC₅₀ = 1.98 μM) against MDA-MB-231 cells compared to chidamide (IC₅₀ = 24.37 μM), inducing 74.15 % inhibition of cell migration and 57.4 % late-stage apoptosis. In vivo studies revealed that 38 (30 mg/kg/day) suppressed tumor growth by 34.78 % without significant toxicity. Collectively, 38 represents a novel dual EGFR/HDAC3 inhibitor that shows promising potential for providing new therapeutic insights into TNBC treatment.</p>\",\"PeriodicalId\":256,\"journal\":{\"name\":\"Bioorganic & Medicinal Chemistry Letters\",\"volume\":\" \",\"pages\":\"130362\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bioorganic & Medicinal Chemistry Letters\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.bmcl.2025.130362\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioorganic & Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.bmcl.2025.130362","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

表皮生长因子受体(EGFR)和组蛋白去乙酰化酶3 (HDAC3)协同推动三阴性乳腺癌(TNBC)的恶性进展。本研究鉴定了一系列n -苄基-2-氟苯甲酰胺衍生物(11-43)为EGFR/HDAC3双靶点抑制剂。其中,化合物38表现出最有希望的活性,对EGFR和HDAC3的IC₅₀值分别为20.34 nM和1.09 μM。分子模型显示,38个分子的2-氟苯甲酰胺部分与Zn2+在HDAC3的活性通道中螯合,而4-氟苯基占据EGFR的atp结合口袋,具有双靶标结合功能。体外实验表明,与奇达酰胺(IC₅₀ = 24.37 μM)相比,38对MDA-MB-231细胞具有优越的抗增殖活性(IC₅₀ = 1.98 μM),诱导74.15% %的细胞迁移抑制和57.4% %的晚期凋亡。体内研究显示,38(30 mg/kg/天)抑制肿瘤生长34.78 %,无明显毒性。总的来说,38代表了一种新的双重EGFR/HDAC3抑制剂,显示出为TNBC治疗提供新的治疗见解的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Discovery and structural-activity relationship of N-benzyl-2-fluorobenzamides as EGFR/HDAC3 dual-target inhibitors for the treatment of triple-negative breast cancer.

Epidermal growth factor receptor (EGFR) and histone deacetylase 3 (HDAC3) synergistically drive malignant progression in triple-negative breast cancer (TNBC). In this study, a series of N-benzyl-2-fluorobenzamide derivatives (11-43) were identified as EGFR/HDAC3 dual-target inhibitors. Among them, compound 38 exhibited the most promising activity, with IC₅₀ values of 20.34 nM and 1.09 μM against EGFR and HDAC3, respectively. Molecular modeling revealed that the 2-fluorobenzamide moiety of 38 chelates with Zn2+ in the active channel of HDAC3, while the 4-fluorobenzyl group occupies the ATP-binding pocket of EGFR, exercising a dual-target binding function. In vitro experiments demonstrated that 38 exhibited superior anti-proliferative activity (IC₅₀ = 1.98 μM) against MDA-MB-231 cells compared to chidamide (IC₅₀ = 24.37 μM), inducing 74.15 % inhibition of cell migration and 57.4 % late-stage apoptosis. In vivo studies revealed that 38 (30 mg/kg/day) suppressed tumor growth by 34.78 % without significant toxicity. Collectively, 38 represents a novel dual EGFR/HDAC3 inhibitor that shows promising potential for providing new therapeutic insights into TNBC treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.70
自引率
3.70%
发文量
463
审稿时长
27 days
期刊介绍: Bioorganic & Medicinal Chemistry Letters presents preliminary experimental or theoretical research results of outstanding significance and timeliness on all aspects of science at the interface of chemistry and biology and on major advances in drug design and development. The journal publishes articles in the form of communications reporting experimental or theoretical results of special interest, and strives to provide maximum dissemination to a large, international audience.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信